Skip to main content

February 2016, Vol 6, No 2

On the Road to Compliance with USP 800: One Private Practice’s Journey

By Robert D. Orzechowski, MBA, SPHR, SHRM-SCP

February 2016, Vol 6, No 2

Medical Professional Liability Claims Challenging for Physicians and Insurers

February 2016, Vol 6, No 2

Midostaurin First Targeted Therapy to Improve Survival in Acute Myeloid Leukemia

By Phoebe Starr

February 2016, Vol 6, No 2

ASH Issues 5 New “Choosing Wisely” Recommendations for Hematologists

February 2016, Vol 6, No 2

Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia

By Phoebe Starr

February 2016, Vol 6, No 2

Medications Used for the Treatment of Kidney Cancers Associated with ICD-10 Codes

By Kristin A. Esposito, CPhT

ICD Codes, Cancer Drug Coding, Reimbursement, Drug Coding

February 2016, Vol 6, No 2

Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer

By Lisa A. Raedler, PhD, RPh

February 2016, Vol 6, No 2

Congress Approves New Funding That Will Affect Cancer Care in 2016

February 2016, Vol 6, No 2

Select Ongoing Trials Currently Enrolling Patients with Kidney Cancers

Clinical Trials Tracker

February 2016, Vol 6, No 2

Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection

By Phoebe Starr

Prostate Cancer

February 2016, Vol 6, No 2

Page 1 of 2